Thursday, March 28, 2024
HomeHealthcareHHS Shines Highlight on Diagnostic Innovation Throughout Lyme Illness

HHS Shines Highlight on Diagnostic Innovation Throughout Lyme Illness


As we mark Lyme Illness Consciousness Month this Could, HHS is proud to have fun the 10 groups collaborating in Section 2 of the LymeX Diagnostics Prize. The last word purpose of HHS and the Steven & Alexandra Cohen Basis’s LymeX Innovation Accelerator (LymeX) competitors is to nurture the event of diagnostics towards Meals and Drug Administration evaluation.

The present two-tier antibody testing system—initially developed in 1994 for illness surveillance, not as a stand-alone diagnostic take a look at—depends on the presence of antibodies and may solely be used precisely 4 to 6 weeks after the affected person turns into contaminated.

Accelerating innovation by means of money prizes and knowledgeable assets

Via September 2023, ten groups are collaborating within the Section 2 digital accelerator, which gives entry to digital studying, mentorship, biorepository subject material experience, and networking alternatives. With prior work in areas starting from sepsis to genetic sequencing and glycomics, the accelerator cohort is making use of a broad vary of experience to their proposed next-generation diagnostics.

By utilizing a prize competitors mannequin, the LymeX Diagnostics Prize gives money prizes alongside a variety of non-monetary assets. The competitors is designed to stimulate the marketplace for Lyme illness diagnostics by serving to entrants overcome diagnostic improvement limitations with prize funds and technical help—whereas additionally fostering cross-disciplinary collaboration.

Enhancing testing accessibility is vital to bettering affected person outcomes, and groups are already starting to contemplate the difficulty with the assistance of scientific research and gadget design assets. Over the summer season, the cohort will take part in roundtable discussions with sufferers and clinicians as they refine their ideas.

The LymeX Diagnostics Prize is setting a brand new bar for innovation in illness diagnostics. If exams are efficiently validated, the cohort’s work may assist enhance Lyme illness therapy general—in addition to exams for different infectious illnesses.

Wanting forward: Knowledgeable judging panel to convene in October 2023

Following the accelerator, the cohort will submit idea papers that element resolution refinement, scientific and affected person enter, and a roadmap from lab to market.

The competitors judging panel—composed of consultants throughout biology, scientific and know-how translation, affected person expertise and advocacy, diagnostic science and know-how, exponential innovation, and ethics—will consider eligible submissions in keeping with official Section 2 analysis standards. Primarily based on the judges’ evaluations, they’ll suggest as much as 5 Section 2 winners of the LymeX Diagnostics Prize.

The Steven & Alexandra Cohen Basis has made a beneficiant $10 million pledge to the LymeX Diagnostics Prize. HHS and the Steven & Alexandra Cohen Basis awarded $1 million in Section 1 of the LymeX Diagnostics Prize, with $9 million in extra LymeX prizes projected to be obtainable in future phases, together with Section 2. A number of accelerator assets shall be made obtainable to the general public on the competitors web site to assist broader innovation in Lyme illness diagnostics and therapy.

To obtain all Section 2 updates, subscribe to the LymeX Diagnostics Prize publication and comply with @Lyme_X on Twitter.



RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments